KAT7 and early-onset autosomal dominant Alzheimer disease: KAT7 (MYST2) has effects on β-catenin or the Wnt inhibitor Dkk1 in Alzheimer's disease positively regulating tau phosphorylation and exacerbating cognitive deficits [71].